• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 3 - The CoMMpass Study

Article

Ms Young addresses MMRF's CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years.

Ms Young addresses MMRF’s CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years. MMRF hopes the CoMMpass study will help researchers and providers better understand the natural history of the disease and “give clues” in terms of how best to treat patients using precision medicine approaches.

Dr Goldberg cautions that getting any early diagnosis can sometimes be problematic in determining whether a patient should start treatment. He also comments on existing and emerging agents for treatment of multiple myeloma.

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.